[February 20, 2013]

Research and Markets: China Healthcare Company Analysis - Nanjing Pharmaceutical

Research and Markets (http://www.researchandmarkets.com/research/lgc7x8/china_healthcare) has announced the addition of the "China Healthcare Company Analysis - Nanjing Pharmaceutical" company profile to their offering.

There are many big local companies that are playing key roles in the Chinese healthcare industry, covering biotech, medical technology and pharmaceutical markets. With more local resources and better understanding of the Chinese market, these local companies had achieved enough shares and are the key competitors of most multinational companies.

Nanjing Pharmaceutical is one of the largest drug distribution and retail companies in China. With its ore than 80 subsidiary companies and strong networks around China, it had achieved revenues of RMB 17.2 billion in 2011. This report will provide you with more insightful information of Nanjing Pharmaceutical, covering its history, business, revenues and costs, people, shareholders and subsidiaries, recent activities and future development.

Reasons of Buying

• More original information based on the Chinese language
• Detailed analysis of the company
• Constantly updated
• Strong after sale support to clients who have access to Shanghai-based experienced analysts for further questions

Who should Buy

• Decision makers who are looking for M&A opportunities in China
• Decision makers who are responsible for market intelligence in China
• Decision makers who are responsible for business development in China
• Investors
• Consultants

Key Topics Covered:

1. Nanjing Pharmaceutical Overview

2. Finance

2.1 Balance Sheet

2.2 Revenues

2.3 Costs

2.4 Profits

3. People

3.1 Board of Director

3.2 Management Team

3.3 Employee

4. Operation

4.1 Risk Analysis

4.2 Recent Activities

4.3 Future Development

For more information visit http://www.researchandmarkets.com/research/lgc7x8/china_healthcare

[ Back To Technology News's Homepage ]